Back to Studies

P1065

Phase I/II Study of Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in HIV-Infected Youth (Versions 1.0 - 3.0) and Open Label Immunogenicity Study of a Booster Dose of MCV4 in Previously Immunized HIV-Infected Children and Youth (Version 4.0)

Study Status

Concluded

DAIDS Number

10396

IND Number

BB 13340

Primary Protocol Team Members

Sharon Nachman Study Vice-Chair
John Sleasman Study Vice-Chair
George Siberry Study Co-Chair
Jorge Lujan-Zilbermann Study Co-Chair
Stephen Spector Immunologist
Scott Watson Westat Representative

Summary

Phase I/II, Study of Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in HIV-Infected Youth (Versions 1.0–3.0) and Open-Label Immunogenicity Study of a Booster Dose of MCV4 in Previously Immunized HIV-Infected Children and Youth (Version 4.0)

Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...